NHS to Prescribe Weight Loss Drug Wegovy to Over a Million Heart Patients
The NHS is significantly expanding access to the weight loss injection Wegovy, with plans to prescribe it to more than a million individuals suffering from heart disease. This initiative aims to prevent heart attacks and strokes, marking a major shift in cardiovascular care.
Approval from National Institute for Health and Care Excellence
The National Institute for Health and Care Excellence (Nice), the NHS's spending watchdog, has approved the use of semaglutide, sold under the brand name Wegovy, for overweight and obese patients with specific heart and circulatory conditions. This approval is based on evidence that the drug reduces the risk of major cardiovascular events.
Clinical trials have indicated that semaglutide not only promotes weight loss but also has direct beneficial effects on the heart and blood vessels. This dual action makes it a valuable tool in preventing life-threatening incidents.
Eligibility and Treatment Guidelines
New guidance stipulates that patients with a body mass index (BMI) of 27 or higher, who are already on other medications like statins, can receive this treatment. It must be used in conjunction with a reduced-calorie diet and increased physical activity.
This expansion is expected to benefit approximately 1.2 million people across England, representing a rapid increase in the number of individuals eligible for such therapies on the health service.
Existing Uses and New Applications
Semaglutide is already available on the NHS for obesity treatment and, under the brand name Ozempic, for type 2 diabetes. The recent approval for cardiovascular prevention underscores its versatility and effectiveness.
Evidence from a clinical trial involving 17,604 participants showed a 20% reduction in the risk of major heart events. Notably, benefits were observed even before significant weight loss, suggesting direct cardiovascular effects.
Cost-Effectiveness and Availability
Nice has deemed the treatment "cost effective" for NHS use. Health service officials anticipate that it will be available within months, providing timely access to those at high risk.
Expert and Official Reactions
Helen Knight, director of medicines evaluation at Nice, emphasized the compelling evidence from trials, stating that semaglutide significantly lowers the likelihood of recurrent heart attacks or strokes when used with existing heart medicines.
Helen Williams, national clinical director for cardiovascular disease prevention at NHS England, described the treatment as "life-changing," offering a powerful new method to protect heart health and improve overall well-being.
Health minister Sharon Hodgson hailed weight loss drugs as a "game changer" in obesity management, noting that extending their use to cardiovascular patients could be lifesaving.
Dr. Sonya Babu-Narayan of the British Heart Foundation highlighted that semaglutide's benefits extend beyond weight reduction, now being recognized as crucial for preventing deadly cardiovascular events.
Juliet Bouverie, chief executive of the Stroke Association, stressed the importance of providing stroke survivors with options to prevent further incidents, especially for those with mobility limitations.
Sebnem Avsar Tuna, general manager for Novo Nordisk UK, welcomed the move as an "important step," enabling clinicians to offer a cost-effective treatment proven to reduce cardiovascular risks.
